2022 American Transplant Congress
Effect of Dual Inhibition of DPP4 and SGLT2 on Tacrolimus-Induced Diabetes Mellitus and Nephrotoxicity in Rat Model
Seoul St.Mary's Hospital, Seoul, Korea, Republic of
*Purpose: Sodium/glucose co-transporter-2 inhibitor (SGLT2i) or dipeptidyl peptidase IV inhibitor (DPP4i) are popular anti-diabetic drugs in type II diabetes mellitus (DM), but their use in…2022 American Transplant Congress
Comparison of Immediate-Release Tacrolimus to Envarsus XR on the Development of Donor Specific Antibodies in Kidney Transplant Recipients
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Major causes of de novo development of donor specific antibodies (DSA) after kidney transplant include medication noncompliance and immunosuppression minimization or elimination that may…2022 American Transplant Congress
Implementing Clinical Decision Support Tools for Immunosuppressant Drug-Drug Interactions to Prevent Graft Failure
1MAPMG, Mc Lean, VA, 2Kaiser Permanente, Silver Spring, MD, 3MAPMG, Rockville, MA
*Purpose: Immunosuppressant drug-drug interactions can result in immunosuppressant toxicity or subtherapeutic levels causing rejection. If not identified and managed appropriately, these interactions may result in…2022 American Transplant Congress
An Interim Report on a Prospective Randomized Trial of Extended-Release Tacrolimus in Liver Transplantation with Anti-Thymocyte Induction in a Steroid Free Protocol
*Purpose: Our study hypothesis was that once daily dosing of extended-release tacrolimus (ERT) would be a safe and effective immunosuppression (IS) with the potential to…2022 American Transplant Congress
Evaluation of Compliance and Efficacy with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Tacrolimus in Kidney Transplant Recipients
*Purpose: The purpose of this study is to evaluate compliance and efficacy of The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype guided tacrolimus…2022 American Transplant Congress
Engineered IL-2 Plus Calcineurin Inhibitor Synergistically Expands Regulatory T Cells Transduced with Engineered IL-2 Receptor and Facilitates Establishment of Transplantation Tolerance
*Purpose: Clinical trials for regulatory T cell (Treg) therapy in organ transplant has shown promising results. However, it is still under the debate which drugs…2022 American Transplant Congress
Differences of Fk-Binding Protein 12 and P-Glycoprotein Explain the Differences in the Intracellular Tacrolimus Concentration of T Lymphocytes and Monocytes
Erasmus MC, Rotterdam, Netherlands
*Purpose: Little is known about the pharmacokinetics of intracellular tacrolimus, particularly in T lymphocytes and monocytes. We demonstrated a significantly lower intracellular tacrolimus concentration in…2021 American Transplant Congress
De-novo Use Comparison Between Extended-release Once-daily Tacrolimus (Envarsus Xr®) and Immediate-release Twice-daily Tacrolimus (Prograf®) – A Single Center’s Experience
*Purpose: Envarsus XR® is approved for de-novo use post-kidney transplantation at a higher starting dose (0.14mg/kg/day) as compared with Prograf® (0.1 mg/kg/day) despite better bioavailability.…2021 American Transplant Congress
The Impact of De Novo Dose-Adjustment Strategies with Tacrolimus XR (LCP-Tac) in Kidney Transplant Recipients
Medical University of South Carolina, Charleston, SC
*Purpose: LCP-Tac is a once daily formulation of tacrolimus indicated for the prophylaxis of rejection in de novo kidney transplant recipients. It provides less variable…2021 American Transplant Congress
The Learning Curve Associated with De Novo Tacrolimus XR Use in a Racially Diverse Kidney Transplant Population
Medical University of South Carolina, Charleston, SC
*Purpose: Tacrolimus XR (LCP-Tac) was approved for de novo dosing in kidney transplant recipients in 2018. In 2020, our center was challenged with a nationwide…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 14
- Next Page »